Orantinib

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.

Product Specifications

CAS Number

[252916-29-3]

Product Name Alternative

SU6668; TSU-68

UNSPSC

12352005

Hazard Statement

H301, H318, H361, H372

Target

Apoptosis; FGFR; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TSU-68.html

Purity

99.29

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(/C=C2C3=CC=CC=C3NC/2=O)NC(C)=C1CCC(O)=O

Molecular Formula

C18H18N2O3

Molecular Weight

310.35

Precautions

H301, H318, H361, H372

References & Citations

[1]Laird AD, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res, 2000, 60 (15), 4152-4160.|[2]Smolich BD, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97 (5), 1413-1421.|[3]Marzola P, et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res, 2004, 10 (2), 739-750.|[4]Kim HC, et al. Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model. Cardiovasc Intervent Radiol. 2012 Feb;35 (1) :168-75